| High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk … EM Van der Elst, J Mbogua, D Operario, G Mutua, C Kuo, P Mugo, ... AIDS and Behavior 17, 2162-2172, 2013 | 303 | 2013 |
| CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa E Karita, N Ketter, MA Price, K Kayitenkore, P Kaleebu, A Nanvubya, ... PloS one 4 (2), e4401, 2009 | 217 | 2009 |
| Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers G Mutua, E Sanders, P Mugo, O Anzala, JE Haberer, D Bangsberg, ... PloS one 7 (4), e33103, 2012 | 185 | 2012 |
| Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa MA Price, CL Wallis, S Lakhi, E Karita, A Kamali, O Anzala, EJ Sanders, ... AIDS research and human retroviruses 27 (1), 5-12, 2011 | 155 | 2011 |
| Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth MA Price, W Rida, M Mwangome, G Mutua, K Middelkoop, S Roux, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 59 (2), 185-193, 2012 | 151 | 2012 |
| Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in … G Mutua, O Anzala, K Luhn, C Robinson, V Bockstal, D Anumendem, ... The Journal of infectious diseases 220 (1), 57-67, 2019 | 119 | 2019 |
| Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures SM Baxi, A Liu, P Bacchetti, G Mutua, EJ Sanders, FM Kibengo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 68 (1), 13-20, 2015 | 99 | 2015 |
| Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial LR Baden, E Karita, G Mutua, LG Bekker, G Gray, L Page-Shipp, ... Annals of internal medicine 164 (5), 313-322, 2016 | 94 | 2016 |
| Utility of different adherence measures for PrEP: patterns and incremental value A Abaasa, C Hendrix, M Gandhi, P Anderson, A Kamali, F Kibengo, ... AIDS and Behavior 22, 1165-1173, 2018 | 65 | 2018 |
| Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission A Kamali, MA Price, S Lakhi, E Karita, M Inambao, EJ Sanders, O Anzala, ... PloS one 10 (1), e0116100, 2015 | 60 | 2015 |
| Safety and immunogenicity of 2-dose heterologous Ad26. ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II … H Barry, G Mutua, H Kibuuka, Z Anywaine, SB Sirima, N Meda, O Anzala, ... PLoS medicine 18 (10), e1003813, 2021 | 58 | 2021 |
| Safety and immunogenicity of 2-dose heterologous Ad26. ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre … Z Anywaine, H Barry, O Anzala, G Mutua, SB Sirima, S Eholie, H Kibuuka, ... PLoS medicine 19 (1), e1003865, 2022 | 56 | 2022 |
| Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya PM Mugo, EJ Sanders, G Mutua, E van der Elst, O Anzala, B Barin, ... AIDS and Behavior 19, 794-801, 2015 | 50 | 2015 |
| A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost … J Mpendo, G Mutua, J Nyombayire, R Ingabire, A Nanvubya, O Anzala, ... PloS one 10 (8), e0134287, 2015 | 49 | 2015 |
| HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya D Bezemer, NR Faria, A Hassan, RL Hamers, G Mutua, O Anzala, ... AIDS research and human retroviruses 30 (2), 118-126, 2014 | 46 | 2014 |
| Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults G Mutua, B Farah, R Langat, J Indangasi, S Ogola, B Onsembe, ... Molecular therapy Methods & clinical development 3, 2016 | 44 | 2016 |
| AIDS vaccines and preexposure prophylaxis: is synergy possible? JL Excler, W Rida, F Priddy, J Gilmour, AB McDermott, A Kamali, O Anzala, ... AIDS research and human retroviruses 27 (6), 669-680, 2011 | 44 | 2011 |
| Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya BA Nyaoke, GN Mutua, R Sajabi, D Nyasani, MW Mureithi, OA Anzala PloS one 12 (9), e0183788, 2017 | 34 | 2017 |
| Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing O Anzala, J Sanders, A Kamali, M Katende, GN Mutua, E Ruzagira, ... East African medical journal 85 (10), 500-504, 2008 | 23 | 2008 |
| Developing standards of care for HIV prevention research in developing countries–a case study of 10 research centers in Eastern and Southern Africa PB Ngongo, F Priddy, H Park, J Becker, B Bender, P Fast, O Anzala, ... AIDS care 24 (10), 1277-1289, 2012 | 22 | 2012 |
